Hikma: US bank says cheap valuation still trumps margin worries

Stifel has reiterated its 'buy' rating on Hikma Pharmaceuticals, despite first-half Injectables division margins slipping to 30% and management cutting full-year guidance to 32-33%. While Stifel trimmed its own long-term margin forecasts, it notes the financial impact is limited, with revenue forecasts rising 2% while operating profit and EPS dip only 1%. The firm believes a second-half recovery to 34% margins is achievable through new product launches, including Tyzavan, and emphasizes the stock's compelling valuation at approximately 10 times forecast earnings and 8 times EV/EBITDA, representing a significant discount to global pharma peers.

Analysis

Stifel has reiterated its 'buy' rating on Hikma Pharmaceuticals, framing the investment case as a valuation argument that outweighs near-term operational concerns. The core issue is profitability in the key Injectables division, where first-half margins of 30% missed expectations of 33%, prompting management to lower full-year guidance from the "mid-30s" to a 32–33% range. Stifel views the required second-half margin recovery to approximately 34% as achievable, predicated on specific catalysts including higher-margin product launches, additional contract manufacturing, and the pivotal launch of Tyzavan before year-end. Despite these positive drivers, Stifel has trimmed its own long-term margin assumptions to a 32-33% band, below the consensus of 35%, citing a less favorable geographic mix skewed towards lower-profitability regions. The financial impact of this forecast adjustment is minimal, with revenue estimates rising 2% while EPS dips just 1%. The central pillar of Stifel's bull thesis is the stock's valuation, which at approximately 10 times forecast earnings and 8 times EV/EBITDA, represents a significant discount to its global pharmaceutical peers, suggesting the margin headwinds are more than priced in.

Key Decisions for Investors

• Investors should consider the compelling valuation case, with Hikma trading at a notable discount to pharma peers at around 10x forward earnings, as a primary reason to look past the recent cut in full-year margin guidance.
• The key near-term catalyst to monitor is the launch of the drug Tyzavan before year-end, as its successful rollout is critical for achieving the required second-half margin rebound to approximately 34% and validating the recovery narrative.
• While Stifel's forecasts remaining below company targets suggests potential for upside, investors must track the impact of the geographic sales mix, as growth in lower-profitability regions in Europe and MENA remains a primary headwind to margins.
• Given the divergence between Stifel's margin outlook (32-33%) and consensus (35%), portfolio managers should assess their own conviction on margin recovery drivers before aligning with the more optimistic Street view.